MacroGenics Yönetim

Yönetim kriter kontrolleri 3/4

MacroGenics' CEO is Scott Koenig, appointed in Sep 2001, has a tenure of 23.17 years. total yearly compensation is $3.71M, comprised of 19% salary and 81% bonuses, including company stock and options. directly owns 2.07% of the company’s shares, worth $5.03M. The average tenure of the management team and the board of directors is 7.8 years and 7.4 years respectively.

Anahtar bilgiler

Scott Koenig

İcra Kurulu Başkanı

US$3.7m

Toplam tazminat

CEO maaş yüzdesi19.0%
CEO görev süresi23.2yrs
CEO sahipliği2.1%
Yönetim ortalama görev süresi7.8yrs
Yönetim Kurulu ortalama görev süresi7.4yrs

Son yönetim güncellemeleri

Recent updates

Party Time: Brokers Just Made Major Increases To Their MacroGenics, Inc. (NASDAQ:MGNX) Earnings Forecasts

Aug 01
Party Time: Brokers Just Made Major Increases To Their MacroGenics, Inc. (NASDAQ:MGNX) Earnings Forecasts

MacroGenics, Inc.'s (NASDAQ:MGNX) Share Price Boosted 29% But Its Business Prospects Need A Lift Too

Jul 30
MacroGenics, Inc.'s (NASDAQ:MGNX) Share Price Boosted 29% But Its Business Prospects Need A Lift Too

We're A Little Worried About MacroGenics' (NASDAQ:MGNX) Cash Burn Rate

Jul 12
We're A Little Worried About MacroGenics' (NASDAQ:MGNX) Cash Burn Rate

MacroGenics, Inc.'s (NASDAQ:MGNX) 81% Dip In Price Shows Sentiment Is Matching Revenues

May 13
MacroGenics, Inc.'s (NASDAQ:MGNX) 81% Dip In Price Shows Sentiment Is Matching Revenues

MacroGenics: Strong Likelihood Bad News Has Caused Overreaction (Rating Upgrade)

May 13

MacroGenics: Positive Safety Update Leads To Two Major Inflection Points In 2024

Apr 05

MacroGenics, Inc. (NASDAQ:MGNX) Surges 27% Yet Its Low P/S Is No Reason For Excitement

Feb 28
MacroGenics, Inc. (NASDAQ:MGNX) Surges 27% Yet Its Low P/S Is No Reason For Excitement

MacroGenics: Trying To Build A Better Everything

Feb 15

There's No Escaping MacroGenics, Inc.'s (NASDAQ:MGNX) Muted Revenues

Jan 09
There's No Escaping MacroGenics, Inc.'s (NASDAQ:MGNX) Muted Revenues

Benign Growth For MacroGenics, Inc. (NASDAQ:MGNX) Underpins Its Share Price

May 17
Benign Growth For MacroGenics, Inc. (NASDAQ:MGNX) Underpins Its Share Price

Analyst Forecasts For MacroGenics, Inc. (NASDAQ:MGNX) Are Surging Higher

Mar 11
Analyst Forecasts For MacroGenics, Inc. (NASDAQ:MGNX) Are Surging Higher

Here's Why MacroGenics (NASDAQ:MGNX) Must Use Its Cash Wisely

Jan 25
Here's Why MacroGenics (NASDAQ:MGNX) Must Use Its Cash Wisely

Analysts' Revenue Estimates For MacroGenics, Inc. (NASDAQ:MGNX) Are Surging Higher

Oct 25
Analysts' Revenue Estimates For MacroGenics, Inc. (NASDAQ:MGNX) Are Surging Higher

MacroGenics: No Near-Term Catalysts

Oct 11

Israel Englander and his Millennium fund disclose 5.2% passive stake in MacroGenics

Sep 02

MacroGenics Q2 2022 Earnings Preview

Aug 05

Companies Like MacroGenics (NASDAQ:MGNX) Could Be Quite Risky

Jul 25
Companies Like MacroGenics (NASDAQ:MGNX) Could Be Quite Risky

MacroGenics halts mid-stage head and neck cancer study after fatalities

Jul 11

The Consensus EPS Estimates For MacroGenics, Inc. (NASDAQ:MGNX) Just Fell Dramatically

May 09
The Consensus EPS Estimates For MacroGenics, Inc. (NASDAQ:MGNX) Just Fell Dramatically

We're Keeping An Eye On MacroGenics' (NASDAQ:MGNX) Cash Burn Rate

Apr 12
We're Keeping An Eye On MacroGenics' (NASDAQ:MGNX) Cash Burn Rate

CEO Tazminat Analizi

Scott Koenig'un ücretlendirmesi MacroGenics'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Jun 30 2024n/an/a

-US$136m

Mar 31 2024n/an/a

-US$23m

Dec 31 2023US$4mUS$705k

-US$9m

Sep 30 2023n/an/a

US$50m

Jun 30 2023n/an/a

US$7m

Mar 31 2023n/an/a

-US$91m

Dec 31 2022US$5mUS$673k

-US$120m

Sep 30 2022n/an/a

-US$191m

Jun 30 2022n/an/a

-US$219m

Mar 31 2022n/an/a

-US$217m

Dec 31 2021US$5mUS$651k

-US$202m

Sep 30 2021n/an/a

-US$146m

Jun 30 2021n/an/a

-US$129m

Mar 31 2021n/an/a

-US$136m

Dec 31 2020US$3mUS$656k

-US$130m

Sep 30 2020n/an/a

-US$158m

Jun 30 2020n/an/a

-US$167m

Mar 31 2020n/an/a

-US$152m

Dec 31 2019US$5mUS$590k

-US$152m

Sep 30 2019n/an/a

-US$166m

Jun 30 2019n/an/a

-US$155m

Mar 31 2019n/an/a

-US$167m

Dec 31 2018US$5mUS$599k

-US$171m

Sep 30 2018n/an/a

-US$21m

Jun 30 2018n/an/a

-US$34m

Mar 31 2018n/an/a

-US$32m

Dec 31 2017US$3mUS$554k

-US$20m

Tazminat ve Piyasa: Scott's total compensation ($USD3.71M) is above average for companies of similar size in the US market ($USD1.48M).

Tazminat ve Kazançlar: Scott's compensation has been consistent with company performance over the past year.


CEO

Scott Koenig (72 yo)

23.2yrs

Görev süresi

US$3,705,825

Tazminat

Dr. Scott Koenig, M.D., Ph D., has been the President and Chief Executive Officer of Macrogenics, Inc. since September 2001. Dr. Koenig is Co-Founder of Macrogenics.He served as Senior Vice President of R...


Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Scott Koenig
President23.2yrsUS$3.71m2.07%
$ 5.0m
James Karrels
Senior VP16.5yrsUS$1.58m0.27%
$ 663.5k
Stephen Eck
Senior VP of Clinical Development & Chief Medical Officer4.3yrsUS$1.75m0.016%
$ 37.9k
Eric Risser
Chief Operating Officer2.8yrsUS$1.92m0.062%
$ 150.5k
Thomas Spitznagel
Senior Vice President of Technical Operations2yrsUS$1.88m0.013%
$ 32.2k
Ezio Bonvini
Senior VP of Research & Chief Scientific Officer8.2yrsUS$2.29m0.16%
$ 390.5k
Jeffrey Peters
Senior VP7.4yrsVeri yok0%
$ 0
Lynn Cilinski
VP, Controller & Treasurer21.1yrsVeri yok0.0099%
$ 24.1k

7.8yrs

Ortalama Görev Süresi

61.5yo

Ortalama Yaş

Deneyimli Yönetim: MGNX's management team is seasoned and experienced (7.8 years average tenure).


Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Scott Koenig
President23.2yrsUS$3.71m2.07%
$ 5.0m
David Stump
Independent Director11.2yrsUS$160.75k0.0072%
$ 17.4k
Federica O'Brien
Independent Director3.8yrsUS$152.00k0.0072%
$ 17.4k
Edward Hurwitz
Independent Director20.1yrsUS$147.63k0.060%
$ 145.4k
Margaret Liu
Independent Director1.8yrsUS$318.32k0.0072%
$ 17.4k
William Heiden
Independent Chairman of the Board2.5yrsUS$180.13k0.0072%
$ 17.4k
Meenu Chhabra Karson
Independent Director1.8yrsUS$335.41k0.0072%
$ 17.4k
Scott Jackson
Independent Director7.8yrsUS$167.63k0.0072%
$ 17.4k
Jay Siegel
Independent Director7yrsUS$167.21k0.0072%
$ 17.4k
Karen Jean Ferrante
Independent Director7.8yrsUS$135.75k0.0072%
$ 17.4k

7.4yrs

Ortalama Görev Süresi

66yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: MGNX's board of directors are considered experienced (7.4 years average tenure).